Enterprise Value
19.7M
Cash
5.153M
Avg Qtr Burn
-7.285M
Short % of Float
10.65%
Insider Ownership
5.16%
Institutional Own.
33.90%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iopofosine (CLR 131) Details Cancer, Multiple myeloma, High Refractory Multiple Myeloma | Phase 2 Data readout | |
Iopofosine (CLR 131) Details Cancer, Waldenstrom macroglobulinemia, Lymphoma Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma | Phase 2 Update | |
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma, B-cell malignancies, Pediatric Sarcomas, High-grade Glioma
| Phase 1b Initiation |